Morgan Stanley has initiated Celldex Therapeutics (NASDAQ:CLDX) at overweight saying that barzolvolimab (barzol), its asset ...

A 27-year-old has been left unable to drink chilled beverages or exercise outdoors in winter after developing a rare cold ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Hanna Newnham, 27, from Brighton, first noticed symptoms of cold urticaria - hives that appear after cold temperature ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

A 27-year-old woman developed a rare cold allergy after Covid-19 and had her first anaphylaxis attack after a McDonald’s ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Dr Ruchi Gupta shares key updates including a new anaphylaxis definition, treatment advances, and emerging biologics for CSU.

HANNA Newnham developed a life-threatening allergy to the cold after catching Covid-19. Now, she can’t exercise outdoors in winter or even enjoy a cold drink. “Even if my throat closes, I’ll keep ...

Morgan Stanley initiated coverage of Celldex (CLDX) with an Overweight rating and $46 price target Celldex is developing antibodies for ...